Xi skips meet with Pak PM as Chinese nationals’ murder takes toll on ties

Islamabad, Jul 3: The US embassy here in a statement on Friday said the Trump administration through the US Agency for International Development (USAID) “donated a shipment of 100 brand-new, state-of-the-art ventilators” to Pakistan.

The ventilators arrived in Karachi on July 2 and will be sent to hospitals across Pakistan.

“This donation delivers on President Donald Trump’s generous offer of these critically-needed supplies and supports Pakistan’s urgent response to the pandemic,” the embassy said.

Made in America, the ventilators are valued at about $3 million and reflect the latest in cutting-edge medical design and technology, it said.

They are compact, easily deployable, and will enable Pakistan to more effectively treat patients suffering from Covid-19.

The US-Pakistan health partnership to curb the spread of the novel coronavirus is helping to improve and expand laboratory testing, disease monitoring, case tracking, infection prevention and control and patient care, the embassy said.

The US has contributed nearly $27 million in new funding so far to this vital partnership that is growing every day. "We are also thankful for Pakistan's contribution of medical supplies to help fight coronavirus in the US," the embassy said in the statement.

Ambassador Paul Jones said, “The US stands with Pakistan in its fight against the coronavirus. These American-made ventilators will help Pakistani patients in the most acute need of medical care."

The announcement comes days after Pakistan said it had started producing locally designed ventilators.

Pakistan reported 78 more deaths from the coronavirus in the past 24 hours, raising virus-related fatalities to 4,551 while the total number of confirmed cases has increased to 221,896.

On Friday, the health authorities said 1,13,623 persons have recovered from the coronavirus, surpassing the number of active Covid-19 infections in the country for the first time.

Johannesburg, Feb 22: To meet shortage of skilled nursing staff, private hospitals in South Africa are recruiting senior Indian nurses for their good work ethics and ability to become efficient trainers for the local staff, according to a media report.

A report at a 2018 jobs summit indicated that the country had a shortage of more than 47,000 nurses.

The shortage of the skilled nursing staff has been attributed to several factors, including preference of highly qualified nurses to emigrate or take up contract employment in countries such as the UK, the United Aarb Emirates, Saudi Arabia or New Zealand for want of higher salaries, a report in the weekly Business Times said.

Mediclinic, one of South Africa's largest private hospital groups, confirmed that it is recruiting 150 nurses from India this year.

“To supplement our training, as an internal strategy, we will continue to recruit senior registered nurses from India,” a Mediclinic spokesperson told the Business Times.

Mediclinic started recruiting nurses from India in 2005 but could not provide details about how many among the more than 8,800 nurses it employs at its hospitals are from India.

Another company, Life Healthcare SA, said it employed 135 Indian nurses between 2008 and 2014.

Top managements at the hospital groups lauded senior Indian nurses as being very efficient trainers for local staff.

“But we find that many of them prefer coming here on short-term contracts due to family commitments," a hospital executive said on the basis of anonymity.

The official said that the few who apply for long-term positions are usually young newly-qualified nurses, which is not the group in demand.

“They work hard, with a patient-oriented work ethic, and do not have the nine-to-five approach of many local nurses, especially those who are unionised," the official said.

“We would be very happy to take in more nursing staff from India," the official added.

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.